Amgen posts upbeat assessment of PhII KRAS data on AMG510 — we just don’t have any idea what researchers saw

It’s not unusual to be left wanting after reading a top-line press release on closely-watched trial data. But Amgen is taking it to a whole new level with its Phase II snapshot on the KRAS G12c drug sotorasib — aka AMG 510. The drug’s one solid shot at breakthrough status…